Related Experiment Video

Updated: May 22, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Anti-angiogenic therapy for colorectal cancer: on the way to getting better!

Kuifeng He1, Ketao Jin, Haohao Wang

  • 1Zhejiang University, School of Medicine, Hangzhou, China.

Hepato-Gastroenterology
|May 15, 2012
PubMed

Insights

Antiangiogenic therapy, including bevacizumab, shows promise for colorectal cancer by inhibiting tumor blood vessel growth. Newer drugs offer diverse mechanisms to overcome resistance and improve patient outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Antiangiogenic therapy targets tumor neovascularization, crucial for cancer growth and metastasis.
  • Bevacizumab, an angiogenesis inhibitor, enhances conventional treatments for colorectal cancer but faces challenges with drug resistance.
  • Diverse antiangiogenic strategies beyond anti-vascular endothelial growth factor are emerging.

Purpose of the Study:

  • To review principal antiangiogenic drugs targeting colorectal cancer.
  • To summarize clinical studies of these agents.
  • To suggest improved future applications of antiangiogenic therapy.

Main Methods:

  • Literature review of antiangiogenic drugs and their mechanisms.
  • Compilation of clinical trial data for colorectal cancer treatment.
  • Analysis of drug resistance and therapeutic outcomes.

Main Results:

  • Bevacizumab demonstrated efficacy but also highlighted resistance issues.
  • Numerous novel antiangiogenic compounds with varied mechanisms are under clinical investigation.
  • Emerging therapies show potential for enhanced antitumor effects.

Conclusions:

  • Antiangiogenic therapy remains a vital strategy for colorectal cancer.
  • Exploring diverse mechanisms is key to overcoming treatment resistance.
  • Further research will refine the clinical use of antiangiogenic agents for improved patient survival.

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.